Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers*
暂无分享,去创建一个
Nils Brünner | Hans Jørgen Nielsen | Rosamonde E Banks | H. Nielsen | N. Brünner | E. Kohn | R. Banks | A. Schrohl | F. Sweep | Fred C G J Sweep | S. Würtz | Anne-Sofie Schrohl | Sidse Würtz | Elise Kohn | S. Würtz
[1] N. Brünner,et al. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection , 2008, Scandinavian journal of gastroenterology.
[2] D. Wagner,et al. Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation , 2005 .
[3] H. Nielsen,et al. Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components , 2002, Scandinavian journal of clinical and laboratory investigation.
[4] T. Mynster. Blood transfusion-induced immunomodulation--is storage time important? , 2003, Danish medical bulletin.
[5] H. Nielsen,et al. Soluble urokinase plasminogen activator receptor in blood transfusion components , 2004, Transfusion medicine.
[6] H. Nielsen,et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.
[7] G. Lippi,et al. Preanalytical variability: the dark side of the moon in laboratory testing , 2006, Clinical chemistry and laboratory medicine.
[8] H. Nielsen,et al. Biological Variation in Circulating Levels of Mannan‐Binding Lectin (MBL) and MBL‐Associated Serine Protease‐2 and the Influence of Age, Gender and Physical Exercise , 2007, Scandinavian journal of immunology.
[9] H. Nielsen,et al. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets , 2002, Scandinavian journal of clinical and laboratory investigation.
[10] H. Nielsen,et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive protein , 2007, Scandinavian journal of clinical and laboratory investigation.
[11] E. Ingham,et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.
[12] Mario Plebani,et al. Errors in laboratory medicine. , 2002, Clinical chemistry.
[13] H. Nielsen,et al. Evaluation of Sample Handling in Relation to Levels of Tissue Inhibitor of Metalloproteinases-1 Measured in Blood by Immunoassay , 2003, The International journal of biological markers.
[14] H. Nielsen,et al. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates , 2001, American journal of hematology.
[15] I. Christensen,et al. Circulating VEGF As a Biological Marker in Patients with Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients , 2007, Disease markers.
[16] N. Brünner,et al. Soluble vascular endothelial growth factor in various blood transfusion components , 1999, Transfusion.
[17] Massimo Gion,et al. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. , 2003, International journal of oncology.
[18] P. Span,et al. Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. , 2007, The Journal of clinical endocrinology and metabolism.
[19] D. Hochstrasser,et al. Impact of preanalytical variables on the analysis of biological fluids in proteomic studies , 2007, Proteomics. Clinical applications.
[20] H. Nielsen,et al. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[21] H. Nielsen,et al. Bacterial antigen-induced release of white cell- and platelet-derived bioactive substances in vitro , 2002, International journal of gastrointestinal cancer.
[22] H. Nielsen,et al. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer , 2008, Scandinavian journal of gastroenterology.
[23] M Plebani,et al. Mistakes in a stat laboratory: types and frequency. , 1997, Clinical chemistry.
[24] H. Nielsen,et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer , 1999, British Journal of Cancer.
[25] H. Nielsen,et al. Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. , 2008, The International journal of biological markers.
[26] Mario Plebani,et al. Errors in a stat laboratory: types and frequencies 10 years later. , 2007, Clinical chemistry.
[27] H. Nielsen,et al. Tissue inhibitor of metalloproteinase‐1 levels in plasma from tumour arteries and veins of patients with rectal cancer , 2007, Scandinavian journal of clinical and laboratory investigation.
[28] E. Brindle,et al. C-reactive protein across the menstrual cycle. , 2008, American journal of physical anthropology.